reports
Genmab Announces Completion of Tender Offer for Outstanding Common Sha...
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolioTransaction anticipated to be accretive to Genmab’s EBITDA by end of 2029 COPENHAGEN, Denmark; December 12, 2025 – (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “Offer”) by Genmab Holding II B.V., a wholly owned subsidia...
- ABGSC Energy Research
- Daniel Vårdal Haugland
- Herman Caspersen
- John Olaisen
- Lars Trongaard Brattli
- Martin Mauseth
- Stian Wibstad
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting Media Release Event to be held virtually via live webcast and archived on Copenhagen, Denmark; December 11, 2025 – (Nasdaq: GMAB) will hold its 2025 R&D Update and ASH Data Review Meeting today, December 11, 2025 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually and can be attended via live webcast. To register for the webcast, click . An archive of the webcast will be available on Genmab’s website. This meeting is not an official program of the ASH Annual Meeting. About Genmab Genmab i...
- ABGSC Energy Research
- John Olaisen
- ABGSC Capital Goods Research
- Benjamin Wahlstedt
- Fredrik Ivarsson
TGS Awarded Streamer 4D Contract Offshore Brazil
TGS Awarded Streamer 4D Contract Offshore Brazil OSLO, Norway (11 December 2025) – TGS, a leading provider of energy data and intelligence, is pleased to announce the award of a streamer 4D contract in the Campos basin, offshore Brazil. A Ramform vessel is scheduled to mobilize for the survey in the second half of 2026, with the contract expected to last approximately 75 days. Kristian Johansen, CEO of TGS, commented, "We are very pleased to secure this 4D streamer contract for an independent energy company in Brazil. By leveraging our purpose-built Ramform designed vessel, equipped wit...
- ABGSC Capital Goods Research
- Benjamin Wahlstedt
- Fredrik Ivarsson
- ABGSC Services Research
- Karl Bokvist
- Simon Jönsson
- ABGSC Capital Goods Research
- Benjamin Wahlstedt
- Fredrik Ivarsson
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting P...
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) Media ReleaseCOPENHAGEN, Denmark; December 8, 2025 Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment option for those unsuitable for chemotherapy Additional early data show promising efficacy of epcoritamab combination regimens in patients with RT Results underscore the potential...
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstra...
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2) resulted in statistically significant and clinically meaningful reduction in the risk of disease progression or death and overall response compared to R2 aloneEPKINLY + R2 was recently approved by the U.S. F...
Genmab Announces Data From Multiple Clinical Trials Showing Treatment ...
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with DLBCL and FLLatest EPCORE DLBCL-3 trial results show encouraging overall response and complete response rates for epcoritamab monotherapy in newly-diagnosed, elderly patients with DLB...
Genmab Announces Closing of Private Offering of Senior Secured Notes a...
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes Media Release COPENHAGEN, Denmark; December 3, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have closed their previously announced offering of $1.5 billion of 6.250% senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of 7.250% senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”). Genmab intends to use the net proceeds from this offe...
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- Lara Mohtadi
VOLV B VOLVO AB CLASS B
WRT1V WARTSILA OYJ ABP
ABB ABB LTD.
SAND SANDVIK AB
TREL B TRELLEBORG AB CLASS B
MOCORP METSO OUTOTEC OYJ
ASSA B ASSA ABLOY AB CLASS B
SKF B SKF AB CLASS B
HPOL B HEXPOL AB CLASS B
ALFA ALFA LAVAL AB
MTRS B MUNTERS GROUP
HEXA B HEXAGON AB
EPI A EPIROC AB
NIBE B NIBE INDUSTRIER AB
ATCO A ATLAS COPCO AB
ALIV SDB AUTOLIV INC.
Transactions With Shares and Linked Securities in Genmab A/S Made by M...
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Company Announcement COPENHAGEN, Denmark; December 1, 2025 – (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their beh...
- ABGSC Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- John Olaisen
- Stian Wibstad
TGS Awarded OBN Contract in Europe
TGS Awarded OBN Contract in Europe OSLO, Norway (1 December 2025) – TGS, a leading provider of energy data and intelligence, is pleased to announce the award of an OBN contract in Europe. The company’s node-on-a-rope crew is scheduled to mobilize early May 2026, and the contract has a duration of approximately 60 days. Kristian Johansen, CEO of TGS, commented, "We are very pleased to secure our first OBN contract for the 2026 season in Europe. The European market currently has several tenders for OBN projects planned for 2026, and our goal is to build a robust acquisition campaign in the ...
- ABGSC Oil & Oil Services Research
- John Olaisen
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Lars Trongaard Brattli
- Martin Mauseth
- Njål Kleiven
- Stian Wibstad
- ABGSC Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- John Olaisen
- Stian Wibstad
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.